Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Memantine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 10/20 | 1.00 |
| ▸ | GRIN2A known ✓ | Q12879 | 10/20 | 1.00 |
| ▸ | GRIN2D known ✓ | O15399 | 9/20 | 1.00 |
| ▸ | GRIN3B known ✓ | O60391 | 9/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 9/20 | 1.00 |
| ▸ | GRIN2C known ✓ | Q14957 | 9/20 | 1.00 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Memantine SCHEMBL2689 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL5606188 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL8126868 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL12959066 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL13198606 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL23327176 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL3053 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL6368832 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2182056 | 0.97 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL25223076 | 0.97 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 40264 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121591615-B | Memantine derivative and synthesis method and application thereof | Shandong Xinhua Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-12636264-B2 | Methods and materials for diagnosis and treatment of neuronal disorder | GENEMO, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122031495-A | Application of isofraxidin in treating neurodegenerative diseases | 中日友好医院(中日友好临床医学研究所) | 2026-05-15 | — | — | CN | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | claimed |
| US-12616706-B2 | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations | Arbormentis LLC (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260115231-A1 | TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS | SPINALCYTE LLC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| WO-1994005275-A9 | METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE | — | 1994-04-28 | — | — | WO | claimed |
| WO-1994006428-A1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| WO-1994005275-A1 | METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-17 | — | — | WO | claimed |
| WO-1994003158-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS HAVING AN EXTENDED TWO-STAGE RELEASE PROFILE AND PRODUCTION THEREOF | MERZ + CO. GMBH & CO. (DE) | 1994-02-17 | — | — | WO | claimed |
| EP-0582186-A1 | Process for producing solid pharmaceutical dosage forms with an extended two-stage release | MERZ + CO. GmbH & Co. (DE) | 1994-02-09 | — | — | EP | claimed |
| WO-1992017168-A1 | METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0139504-B1 | ADAMANTYLAMINE/LONG CHAIN ALKYLAMINE CATALYSTS AND USE IN PARAFFIN-OLEFIN ALKYLATION PROCESS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1988-06-08 | — | — | EP | claimed |
| EP-0139504-A1 | Adamantylamine/long chain alkylamine catalysts and use in paraffin-olefin alkylation process | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-05-02 | — | — | EP | claimed |
| US-4273774-A | 1,3-DIMETHYL-5-AMINOADMANTANE TOGETHER WITH CAFFEINE OR THEOPHYLLINE | MERZ & CO. (DE) | 1981-06-16 | — | — | US | claimed |
| US-4122193-A | 1-AMINO-3,5-DIMETHYL-ADAMANTANE, ANTI-HYPERKINESIS | MERZ & CO. (DE) | 1978-10-24 | — | — | US | claimed |